Drug Information

Drug General Information
Drug ID
D04BFU
Former ID
DNC005485
Drug Name
LIDORESTAT
Drug Type
Small molecular drug
Indication Diabetic complication [ICD10:E08-E13] Phase 2 [521528], [542435]
Formula
C18H11F3N2O2S
InChI
InChI=1S/C18H11F3N2O2S/c19-11-6-12(20)18-17(16(11)21)22-14(26-18)5-9-7-23(8-15(24)25)13-4-2-1-3-10(9)13/h1-4,6-7H,5,8H2,(H,24,25)
InChIKey
KYHVTMFADJNSGS-UHFFFAOYSA-N
PubChem Compound ID
157839
PubChem Substance ID
10253202, 10322123, 14853356, 17137025, 46233367, 46516704, 57348431, 78894725, 99443534, 103463246, 113438420, 134342690, 135113619, 137054477, 142372420, 160968148, 162496940, 178103983, 179150215, 198982860, 223739551, 226744847, 241054518, 243669426
Target and Pathway
Target(s) Aldose reductase Target Info Inhibitor [527533]
BioCyc Pathway Methylglyoxal degradation III
Acetone degradation I (to methylglyoxal)
KEGG Pathway Pentose and glucuronate interconversions
Fructose and mannose metabolism
Galactose metabolism
Glycerolipid metabolism
Metabolic pathways
NetPath Pathway IL1 Signaling Pathway
TGF_beta_Receptor Signaling Pathway
PathWhiz Pathway Fructose and Mannose Degradation
Pyruvate Metabolism
Pterine Biosynthesis
Glycerolipid Metabolism
Galactose Metabolism
WikiPathways Metapathway biotransformation
Polyol Pathway
Metabolism of steroid hormones and vitamin D
References
Ref 521528ClinicalTrials.gov (NCT00043797) Lidorestat (IDD 676) for the Treatment of Diabetic Neuropathy. U.S. National Institutes of Health.
Ref 542435(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7411).
Ref 527533J Med Chem. 2005 May 5;48(9):3141-52.Discovery of 3-[(4,5,7-trifluorobenzothiazol-2-yl)methyl]indole-N-acetic acid (lidorestat) and congeners as highly potent and selective inhibitors of aldose reductase for treatment of chronic diabetic complications.